Search Results - "O’Leary, J.G."

24 HIGH MFI PREFORMED CLASS II DONOR SPECIFIC ANTIBODIES ACCELERATE FIBROSIS AND INCREASE MORTALITY AFTER LIVER TRANSPLANT IN HCV-INFECTED PATIENTS by O'Leary, J.G, Kaneku, H, Jennings, L.W, Susskind, B.M, Terasaki, P.I, Klintmalm, G.B

Get full text

P905 THE RISK OF DELISTING OR DEATH IN LIVER TRANSPLANT CANDIDATES INCREASES FOLLOWING INFECTIONS: RESULTS FROM THE NACSELD CONSORTIUM by O'Leary, J.G, Bajaj, J.S, Wong, F, Kamath, P.S, Biggins, S.W, Patton, H.M, Fallon, M.B, Garcia-Tsao, G, Subramanian, R.M, Maliakkal, B.J, Malik, R, Thacher, L.R, Reddy, K.R

Get full text

P502 SPONTANEOUS BACTERIAL PERITONITIS AND BACTEREMIA PREDICT MORTALITY IN CIRRHOSIS DESPITE PROPHYLACTIC MEASURES: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELD by Biggins, S.W, O'Leary, J.G, Reddy, K.R, Wong, F, Kamath, P.S, Patton, H.M, Fallon, M.B, Garcia-Tsao, G, Subramanian, R.M, Thuluvath, P, Maliakkal, B, Koch, D, Malik, R, Thacker, L.R, Bajaj, J.S

Get full text

83 THE NEW CONSENSUS DEFINITION OF ACUTE KIDNEY INJURY IS VALID IN PREDICTING MORTALITY IN HOSPITALIZED INFECTED CIRRHOTIC PATIENTS: THE NACSELD EXPERIENCE by Wong, F, O'leary, J.G, Reddy, K.R, Patton, H, Kamath, P.S, Fallon, M.B, Garcia-Tsao, G, Subramanian, R.M, Maliakkal, B, Thacker, L.R, Bajaj, J.S

Get full text

23 A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP by Verna, E.C, Burton, J.R, O'Leary, J.G, Lai, J.C, Saxena, V, Dodge, J.L, Everson, G.T, Trotter, J.F, Stravitz, R.T, Brown, R.S, Terrault, N.A

Get full text

226 LONG-TERM ANTIBIOTIC AND PROTON-PUMP INHIBITOR USE ARE STRONG PREDICTORS OF RECURRENT INFECTIONS IN CIRRHOSIS: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELD by O'Leary, J.G, Reddy, K.R, Wong, F, Kamath, P.S, Patton, H.M, Biggins, S.W, Fallon, M.B, Garcia-Tsao, G, Subramanian, R.M, Brown, G, Malik, R, Thacker, L.R, Bajaj, J.S

Get full text

IN-HOSPITAL MORTALITY IN CIRRHOSIS IS RELATED TO NOSOCOMIAL INFECTIONS INDEPENDENT OF MELD SCORE: THE NORTH AMERICAN CONSORTIUM FOR THE STUDY OF END-STAGE LIVER DISEASE (NACSELD) STUDY by Bajaj, J.S, O'Leary, J.G, Reddy, K.R, Olson, J.C, Wong, F, Brown, G, Subramanian, R, Malik, R, Thacker, L.R, Noble, N.A, Kamath, P.S

Get full text

De Novo Donor‐Specific HLA Antibodies Decrease Patient and Graft Survival in Liver Transplant Recipients by Kaneku, H., O'Leary, J. G., Banuelos, N., Jennings, L. W., Susskind, B. M., Klintmalm, G. B., Terasaki, P. I.

“…The role of de novo donor‐specific HLA antibodies (DSA) in liver transplantation remains unknown as most of the previous studies have only focused on preformed…”
Get full text

Impact of IgG3 Subclass and C1q‐Fixing Donor‐Specific HLA Alloantibodies on Rejection and Survival in Liver Transplantation by O'Leary, J. G., Kaneku, H., Banuelos, N., Jennings, L. W., Klintmalm, G. B., Terasaki, P. I.

“…Recent literature confirms donor‐specific HLA alloantibodies (DSA) impair 5‐year survival in some but not all liver transplant recipients. In an effort to…”
Get full text

Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts by O’Leary, J.G., Cai, J., Freeman, R., Banuelos, N., Hart, B., Johnson, M., Jennings, L.W., Kaneku, H., Terasaki, P.I., Klintmalm, G.B., Demetris, A.J.

“…Donor-specific alloantibodies (DSA) can cause acute antibody-mediated rejection (AMR) in all solid organ allografts. However, long-term outcome in patients…”
Get full text

The Role of Donor‐Specific HLA Alloantibodies in Liver Transplantation by O'Leary, J. G., Demetris, A. J., Friedman, L. S., Gebel, H. M., Halloran, P. F., Kirk, A. D., Knechtle, S. J., McDiarmid, S. V., Shaked, A., Terasaki, P. I., Tinckam, K. J., Tomlanovich, S. J., Wood, K. J., Woodle, E. S., Zachary, A. A., Klintmalm, G. B.

“…The impact of donor‐specific HLA alloantibodies (DSA) on short‐ and long‐term liver transplant outcome is not clearly defined. While it is clear that not all…”
Get full text

Bortezomib for Acute Antibody‐Mediated Rejection in Liver Transplantation by Paterno, F., Shiller, M., Tillery, G., O’Leary, J. G., Susskind, B., Trotter, J., Klintmalm, G. B.

“…Antibody‐mediated rejection (AMR) is an uncommon, but challenging type of rejection after solid organ transplantation. We review three cases of AMR in…”
Get full text

Class II Alloantibody and Mortality in Simultaneous Liver‐Kidney Transplantation by O'Leary, J. G., Gebel, H. M., Ruiz, R., Bray, R. A., Marr, J. D., Zhou, X. J., Shiller, S. M., Susskind, B. M., Kirk, A. D., Klintmalm, G. B.

“…Hyperacute kidney rejection is unusual in crossmatch positive recipients of simultaneous liver–kidney transplants (SLKT). However, recent data suggest that…”
Get full text

Protecting the Kidney in Liver Transplant Recipients: Practicee-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice by Levitsky, J., O’Leary, J.G., Asrani, S., Sharma, P., Fung, J., Wiseman, A., Niemann, C.U.

Get full text

Efficacy and Patient-Reported Outcomes in Decompensated Cirrhotic with Chronic Hepatitis C Treated with Sofosbuvir and Velpatasvir with or without Ribavirin: Results from Astral-4 Clinical Trial by Younossi, Z.M, Stepanova, M, Charlton, M, O’Leary, J.G, Curry, M.P, Brown, R.S, Hunt, S

Get full text

NACSELD acute-on-chronic liver failure (NACSELD-ACLF) predicts 30-day mortality in admitted cirrhotic patients by O’leary, J.G, Reddy, K.R, Tanson, P, Kamath, P.S, Wong, F, Garcia-Tsao, G, Lai, J, Biggins, S, Fallon, M.B, Subramanian, R, Thuluvath, P, Maliakkal, B, Thacker, L, Bajaj, J.S

Get full text

Impressive Gains in Patient-Reported Outcomes are Observed in Chronic Hepatitis C Patients with or without Cirrhosis who are Treated with Sofosbuvir and Velpatasvir: Results from Astral-1, -2, -3 and-4 by Younossi, Z.M, Stepanova, M, Feld, J, Zeuzem, S, Sulkowski, M, Foster, G.R, Mangia, A, Charlton, M, O’Leary, J.G, Curry, M.P, Hunt, S

Get full text

Efficacy and Safety of Simeprevir and Sofosbuvir with and without Ribavirin for 12 Weeks in Subjects with Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Galaxy Study by O’Leary, J.G, Brown, K, Burton, J, Firpi-Morell, R, Fontana, R.J, Muir, A, O’Brien, C, Rabinovitz, M, Rajender Reddy, K, Ryan, R, Shprecher, A, Villadiego, S, Prabhakar, A, Brown, R.S

Get full text

Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival by Bhutta, A.Q, Garcia-Tsao, G, Reddy, R, Tandon, P, Wong, F, O’Leary, J.G, Acharya, C, Banerjee, D, Abraldes, J.G, Plener, I, Jones, T.M, Shaw, J, Deng, Y, Ciarleglio, M, Bajaj, J.S

Get full text

Resistance Analysis in 1284 Patients with Genotype 1 to 6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Astral-1, Astral-2, Astral-3 and Astral-4 Studies by Hezode, C, Reau, N, Svarovskaia, E, Doehle, B.P, Chodavarapu, K, Dvory-Sobol, H, Mcnally, J, Osinusi, A, Brainard, D.M, Miller, M.D, Mo, H, Roberts, S, O’leary, J.G

Get full text